Huyang Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Huyang Xie has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Jiejie Xu
National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
26 shared publications Yu Zhu
26 shared publicationsBo Dai
25 shared publicationsHangcheng Fu
25 shared publicationsZheng Liu
24 shared publicationsJunyu Zhang
23 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , 5817314
Mendelian Randomization Identified SLC2A9 as a Novel cis‐eQTL‐Mediated Susceptibility Gene in Suppressing Renal Cancer and Its Related Metabolic Mechanisms
Objective: Mendelian randomization (MR) analysis has currently been widely used in combination with expression quantitative trait loci (eQTLs) or cis‐eQTLs for identifying novel drug targets in various diseases. Hence in this article, we first integrated MR analysis with eQTLs and cis‐eQTLs to reveal the causal effects among SLC2A9 and renal cancer (RC), along with its related metabolic mechanisms. Methods: Related genome‐wide association study (GWAS) data were obtained from online datasets. Two‐sample MR and summary‐data‐based MR study (SMR) analyses were applied to assess the causal effects among SLC2A9 eQTL or cis‐eQTLs and RC, respectively. Sensitivity analysis confirmed the robustness and heterogeneity of the results. Besides, 1400 metabolites were enrolled as mediators to further reveal the related metabolic mechanisms of SLC2A9 eQTL involved in RC. Results: Our results found that SLC2A9 eQTL was markedly associated with low risks of RC in the IEU OpenGWAS eQTLs dataset (discovering) ( p = 0.030). The eQTLGEN and GTEx Whole Blood datasets validated the causal effects among SLC2A9 cis‐eQTL and RC, reducing RC risks (both p < 0.05). The TCGA‐KIRC and the CPTAC‐KIRC datasets validated the mRNA and protein expression levels of SLC2A9 in RC, confirming its antitumor roles in RC (both p < 0.05). A total of five metabolites were finally identified to reveal the related metabolic mechanisms of SLC2A9 eQTL involved in RC (all p < 0.05). Conclusions: This study indicated that SLC2A9 eQTL or cis‐eQTL was markedly associated with low risks of RC and played an antitumor role in RC, along with preliminary identification of five metabolic pathways for its potential mechanisms requiring further investigation.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , 5817314
Open AccessMendelian Randomization Identified SLC2A9 as a Novel cis‐eQTL‐Mediated Susceptibility Gene in Suppressing Renal Cancer and Its Related Metabolic Mechanisms
Objective: Mendelian randomization (MR) analysis has currently been widely used in combination with expression quantitative trait loci (eQTLs) or cis‐eQTLs for identifying novel drug targets in various diseases. Hence in this article, we first integrated MR analysis with eQTLs and cis‐eQTLs to reveal the causal effects among SLC2A9 and renal cancer (RC), along with its related metabolic mechanisms. Methods: Related genome‐wide association study (GWAS) data were obtained from online datasets. Two‐sample MR and summary‐data‐based MR study (SMR) analyses were applied to assess the causal effects among SLC2A9 eQTL or cis‐eQTLs and RC, respectively. Sensitivity analysis confirmed the robustness and heterogeneity of the results. Besides, 1400 metabolites were enrolled as mediators to further reveal the related metabolic mechanisms of SLC2A9 eQTL involved in RC. Results: Our results found that SLC2A9 eQTL was markedly associated with low risks of RC in the IEU OpenGWAS eQTLs dataset (discovering) ( p = 0.030). The eQTLGEN and GTEx Whole Blood datasets validated the causal effects among SLC2A9 cis‐eQTL and RC, reducing RC risks (both p < 0.05). The TCGA‐KIRC and the CPTAC‐KIRC datasets validated the mRNA and protein expression levels of SLC2A9 in RC, confirming its antitumor roles in RC (both p < 0.05). A total of five metabolites were finally identified to reveal the related metabolic mechanisms of SLC2A9 eQTL involved in RC (all p < 0.05). Conclusions: This study indicated that SLC2A9 eQTL or cis‐eQTL was markedly associated with low risks of RC and played an antitumor role in RC, along with preliminary identification of five metabolic pathways for its potential mechanisms requiring further investigation.
- Open Access
- 2 August 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-9
Predictive value of inflammatory marker PLR in prostate cancer
This study aims to investigate the correlation between inflammatory markers and prostate cancer with a good-quality predictive model. The original dataset was randomly split into a training set (70%) and a validation set (30%). Logistic regression was used to examine the related risk factors within the training set. ROC curve analysis was conducted to evaluate the discriminative ability of risk factors for PCa. The accuracy and performance of the prediction model were evaluated using the clinical decision curve and 10-fold cross-validation. The diagnostic value of the model was compared across various PSA regions in the entire dataset. The nomogram was employed to illustrate the predictive model. Additionally, we analyzed the corresponding variables and the relationship between the International Society of Urological Pathology (ISUP) grading of PCa. Age, prostate volume (PV), total PSA (tPSA), (f/t) PSA, and platelet-to-lymphocyte ratio were identified as independent risk factors for prostate cancer. The predictive model utilizing these parameters has shown significant clinical advantage, stability, and elevated diagnostic efficacy within the PSA range of 4–20 ng/mL. Additionally, significant differences in tPSA and PV were observed among PCa patients with varying ISUP grades. PLR can serve as a predictive indicator for prostate cancer and, when integrated with additional clinical data, can enhance the detection rate of prostate cancer. Moreover, there was no correlation between PLR and the ISUP grade of PCa.
- 2 August 2025
- Published by Springer Nature in BMC Urology
- Vol. 25 (1) , 1-9
Open AccessPredictive value of inflammatory marker PLR in prostate cancer
This study aims to investigate the correlation between inflammatory markers and prostate cancer with a good-quality predictive model. The original dataset was randomly split into a training set (70%) and a validation set (30%). Logistic regression was used to examine the related risk factors within the training set. ROC curve analysis was conducted to evaluate the discriminative ability of risk factors for PCa. The accuracy and performance of the prediction model were evaluated using the clinical decision curve and 10-fold cross-validation. The diagnostic value of the model was compared across various PSA regions in the entire dataset. The nomogram was employed to illustrate the predictive model. Additionally, we analyzed the corresponding variables and the relationship between the International Society of Urological Pathology (ISUP) grading of PCa. Age, prostate volume (PV), total PSA (tPSA), (f/t) PSA, and platelet-to-lymphocyte ratio were identified as independent risk factors for prostate cancer. The predictive model utilizing these parameters has shown significant clinical advantage, stability, and elevated diagnostic efficacy within the PSA range of 4–20 ng/mL. Additionally, significant differences in tPSA and PV were observed among PCa patients with varying ISUP grades. PLR can serve as a predictive indicator for prostate cancer and, when integrated with additional clinical data, can enhance the detection rate of prostate cancer. Moreover, there was no correlation between PLR and the ISUP grade of PCa.
- Open Access
- 11 April 2024
- Published by Springer Nature in BMC Urology
- Vol. 24 (1) , 1-13
Elevated ADH5 expression suggested better prognosis in kidney renal clear cell carcinoma (KIRC) and related to immunity through single-cell and bulk RNA-sequencing
Despite the rapid advances in modern medical technology, kidney renal clear cell carcinoma (KIRC) remains a challenging clinical problem in urology. Researchers urgently search for useful markers to break through the therapeutic conundrum due to its high lethality. Therefore, the study explores the value of ADH5 on overall survival (OS) and the immunology of KIRC. The gene expression matrix and clinical information on ADH5 in the TCGA database were validated using external databases and qRT-PCR. To confirm the correlation between ADH5 and KIRC prognosis, univariate/multivariate Cox regression analysis was used. We also explored the signaling pathways associated with ADH5 in KIRC and investigated its association with immunity. The mRNA and protein levels showed an apparent downregulation of ADH5 in KIRC. Correlation analysis revealed that ADH5 was directly related to histological grade, clinical stage, and TMN stage (p < 0.05). Univariate and multivariate Cox regression analysis identified ADH5 as an independent factor affecting the prognosis of KIRC. Enrichment analysis looked into five ADH5-related signaling pathways. The results showed no correlation between ADH5 and TMB, TNB, and MSI. From an immunological perspective, ADH5 was found to be associated with the tumor microenvironment, immune cell infiltration, and immune checkpoints. Lower ADH5 expression was associated with greater responsiveness to immunotherapy. Single-cell sequencing revealed that ADH5 is highly expressed in immune cells. ADH5 could be a promising prognostic biomarker and a potential therapeutic target for KIRC. Besides, it was found that KIRC patients with low ADH5 expression were more sensitive to immunotherapy.
- 11 April 2024
- Published by Springer Nature in BMC Urology
- Vol. 24 (1) , 1-13
Open AccessElevated ADH5 expression suggested better prognosis in kidney renal clear cell carcinoma (KIRC) and related to immunity through single-cell and bulk RNA-sequencing
Despite the rapid advances in modern medical technology, kidney renal clear cell carcinoma (KIRC) remains a challenging clinical problem in urology. Researchers urgently search for useful markers to break through the therapeutic conundrum due to its high lethality. Therefore, the study explores the value of ADH5 on overall survival (OS) and the immunology of KIRC. The gene expression matrix and clinical information on ADH5 in the TCGA database were validated using external databases and qRT-PCR. To confirm the correlation between ADH5 and KIRC prognosis, univariate/multivariate Cox regression analysis was used. We also explored the signaling pathways associated with ADH5 in KIRC and investigated its association with immunity. The mRNA and protein levels showed an apparent downregulation of ADH5 in KIRC. Correlation analysis revealed that ADH5 was directly related to histological grade, clinical stage, and TMN stage (p < 0.05). Univariate and multivariate Cox regression analysis identified ADH5 as an independent factor affecting the prognosis of KIRC. Enrichment analysis looked into five ADH5-related signaling pathways. The results showed no correlation between ADH5 and TMB, TNB, and MSI. From an immunological perspective, ADH5 was found to be associated with the tumor microenvironment, immune cell infiltration, and immune checkpoints. Lower ADH5 expression was associated with greater responsiveness to immunotherapy. Single-cell sequencing revealed that ADH5 is highly expressed in immune cells. ADH5 could be a promising prognostic biomarker and a potential therapeutic target for KIRC. Besides, it was found that KIRC patients with low ADH5 expression were more sensitive to immunotherapy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Univariate Cox Regression Analysis of 22 immune phenotypes and overall survival with TCGA database
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Univariate Cox Regression Analysis of 22 immune phenotypes and overall survival with TCGA database
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Correlation between immune phenotypes and immune check point molecule expression with TCGA cohort
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Correlation between immune phenotypes and immune check point molecule expression with TCGA cohort
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Univariable Cox Regression Analysis of 10 Immune Phenotypes and Overall Survival in the Training Cohort, Testing Cohort
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Univariable Cox Regression Analysis of 10 Immune Phenotypes and Overall Survival in the Training Cohort, Testing Cohort
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Antibody sources and staining conditions
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Antibody sources and staining conditions
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Univariable Cox Regression Analysis of the stromal immunotype, Clinical variables, and Survival in the Training Cohort, Testing cohort and Validation Cohort
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Univariable Cox Regression Analysis of the stromal immunotype, Clinical variables, and Survival in the Training Cohort, Testing cohort and Validation Cohort
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Correlate Immunotype with disease-free survival in training cohort, testing cohort and validation cohort
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Correlate Immunotype with disease-free survival in training cohort, testing cohort and validation cohort